Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The journal of nutrition, health & aging
Metadata
Title
Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy
Authors
C. Wischik
R. Staff
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
The journal of nutrition, health & aging / Issue 4/2009
Print ISSN: 1279-7707
Electronic ISSN: 1760-4788
DOI
https://doi.org/10.1007/s12603-009-0046-5

Other articles of this Issue 4/2009

The journal of nutrition, health & aging 4/2009 Go to the issue

JNHA: Geriatric Science

Defining frailty — the holy grail of geriatric medicine

Editorial

Use of biomarkers in Alzheimer’s trials

Frailty: Defining and Measuring of a Concept

Frailty: Defining and measuring of a concept

JNHA: Clinical Trials and Aging

Interpreting biomarker data in therapeutic trials

JNHA: Clinical Trials and Aging

What we have learned from the xaliproden Sanofi-aventis trials

Biomarkers for Alzheimer’s Disease Trials — Biomarkers for What? A Discussion Paper

Biomarkers for Alzheimer’s disease trials — biomarkers for what? A discussion paper
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits